// App-Quantinova.ai

4125 : Investigating determinants of sensitivity to ATR inhibition, as predictive biomarkers to single agent ATR inhibitor, VE-821, in ovarian cancer

Researchers

Presenter

  • Alice Mary Bradbury

Principal Investigators

  • Frank T. Zenke

  • Yvette Drew

  • Nicola J. Curtin

Medical Centers

  • Newcastle University, Newcastle upon Tyne, United Kingdom

  • Merck KGaA, Darmstadt, Germany

Locations

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • High grade serous ovarian cancer

  • Ovarian cancer

Biomarkers

  • Ataxia Telangiectasia And Rad3-Related Protein

  • AT-rich interactive domain 1A

  • Tumor protein p53

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • VE821

  • VX970

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved